Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Guidelines on the management of massive blood loss.

BIBLIOGRAPHIC SOURCE(S)

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

A summary of key recommendations is presented as a template that can be modified to suit local circumstances, and then displayed in clinical areas. The left-hand column outlines the key steps or goals, the centre column adds procedural detail and the right-hand column provides additional advice and information (Table below).

Table I. Summary of Key Recommendations


Goal Procedure Comments
Restore circulating volume Insert wide bore peripheral or central cannulae

Give pre-warmed crystalloid or colloid as needed

Avoid hypotension or urine output <0.5 ml/kg/h
14 gauge

Monitor central venous pressure

Keep patient warm

Concealed blood loss is often underestimated
Contact key personnel Clinician in charge

Consultant anaesthetist

Blood transfusion Biomedical Scientist

Haematologist
A named senior person must take responsibility for communication and documentation.

Arrange Intensive Care Unit bed
Arrest bleeding Early surgical or obstetric intervention

Interventional radiology
 
Request laboratory investigations FBC, PT, APTT, Thrombin time, Fibrinogen (Clauss method); blood bank sample, biochemical profile, blood gases and pulse oximetry

Ensure correct sample identification

Repeat tests after blood component infusion
Results may be affected by colloid infusion

Ensure correct patient identification

May need to give components before results available
Maintain Hb >8 g/dl Assess degree of urgency  
Employ blood salvage to minimise allogeneic blood use Collection of spilt blood can be set up in <10 min
Give red cells  

Group O Rh D negative

 

In extreme emergency

D positive is acceptable if patient is male or postmenopausal female

Until ABO and Rh D groups known

ABO group specific when blood group known

 

Fully compatible blood

Time permitting

Further serological crossmatch not required after 1 blood volume replacement
Use blood warmer and/or rapid infusion device if flow rate >50 ml/kg/h in adult Transfusion laboratory will complete crossmatch after issue
Maintain platelet count >75 x 109/l Allow for delivery time from blood centre

Anticipate platelet count <50 x 109/l. after 2 x blood volume replacement
Allows margin of safety to ensure platelet count >50 x 109/l

Keep platelet count >100 x 109./l if multiple or CNS trauma or if platelet function abnormal
Maintain PT & APTT <1.5 × mean control Give FFP 12 to 15 ml/kg (1 l or four units for an adult) guided by tests

Anticipate need for FFP after 1 to 1.5 x blood volume replacement

Allow for 30 min thawing time
PT/APTT >1.5 x mean normal value correlates with increased microvascular bleeding

Keep ionised Ca2+ >1.13 mmol/l
Maintain Fibrinogen >1.0 g/l If not corrected by FFP give cryoprecipitate (Two packs of pooled cryoprecipitate for an adult)

Should be available on-site. Allow for 30 min thawing time
Cryoprecipitate rarely needed except in DIC
Avoid DIC Treat underlying cause (shock, hypothermia, acidosis) Although rare, mortality is high

FBC, full blood count; PT, prothrombin time; APTT, activated partial thromboplastin time; FFP, fresh frozen plasma; DIC, disseminated intravascular coagulation

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Recommendations are based on appraisal of the relevant literature and expert consensus.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2006 Dec

GUIDELINE DEVELOPER(S)

British Committee for Standards in Haematology - Professional Association

GUIDELINE DEVELOPER COMMENT

Not applicable

SOURCE(S) OF FUNDING

British Committee for Standards in Haematology

GUIDELINE COMMITTEE

Writing Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Writing Group Members: D. Stainsby, National Blood Service; S. MacLennan, National Blood Service; D. Thomas, Morriston Hospital, Swansea; J. Isaac, University Hospitals, Birmingham; P. J. Hamilton, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Task Force Members: Dr Frank Boulton (Chair); Dr Dorothy Stainsby (Secretary); Ms Andrea Blest; Dr Hari Boralessa; Dr Hannah Cohen; Mr Chris Elliott; Dr Brian McClelland; Dr Hafiz Qureshi; Dr Megan Rowley; Dr Gillian Turner; Dr Keith Wilson

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

None of the authors has declared a conflict of interest.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available from the British Committee for Standards in Haematology Web site.

Print copies: Available from the British Committee for Standards in Haematology; Email: bcsh@b-s-h.org.uk.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on May 27, 2008. The information was verified by the guideline developer on June 30, 2008.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo